Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2). The compounds are bicyclic inhibitors of histone deacetylase, useful for treating neurological disorders, memory or cognitive function disorders or impairments, extinction learning disorders, fungal diseases or infections, inflammatory diseases, hematological diseases, neoplastic diseases, psychiatric disorders, and memory loss.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
May 21, 2024
Assignee:
Alkermes, Inc.
Inventors:
Nathan Oliver Fuller, John A. Lowe, III
Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent.
Type:
Grant
Filed:
August 10, 2021
Date of Patent:
April 30, 2024
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Type:
Grant
Filed:
June 1, 2023
Date of Patent:
April 9, 2024
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
February 27, 2024
Assignee:
Alkermes, Inc.
Inventors:
Nathan Oliver Fuller, John A. Lowe, III
Abstract: The present invention provides compounds of formula (I), wherein: R1 is unsubstituted C1-C6 alkyl; La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and R2 and R3 are each, independently, H, substituted or unsubstituted C1-C6 alkyl, or substituted or unsubstituted C6-C10aryl; or alternatively, R2 and R3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.
Type:
Grant
Filed:
December 9, 2021
Date of Patent:
February 20, 2024
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
Type:
Grant
Filed:
March 24, 2021
Date of Patent:
January 30, 2024
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
Abstract: This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.
Type:
Grant
Filed:
December 28, 2020
Date of Patent:
January 2, 2024
Assignee:
Alkermes, Inc.
Inventors:
Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
December 5, 2023
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Jared Lopes, Heather C. Losey, Raymond J. Winquist
Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
Type:
Grant
Filed:
December 20, 2021
Date of Patent:
September 19, 2023
Assignee:
Alkermes, Inc.
Inventors:
Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Type:
Grant
Filed:
December 3, 2021
Date of Patent:
August 8, 2023
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
Abstract: Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Type:
Grant
Filed:
June 30, 2022
Date of Patent:
July 25, 2023
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
Type:
Grant
Filed:
November 25, 2020
Date of Patent:
January 3, 2023
Assignee:
Alkermes, Inc.
Inventors:
Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
Abstract: The present application relates methods for treating a depressive symptom comprising administering an effective amount of a ? opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.
Type:
Grant
Filed:
June 26, 2020
Date of Patent:
December 27, 2022
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Abstract: The invention provides compositions and methods for modulating the immunostimulatory properties and/or anti-inflammatory properties of IL-10. The present invention provides scIL-10 polypeptides of Formula 1. The polypeptides of the invention are optionally linked to a fusion partner. The polypeptides of Formula 1 are referred to herein as “scIL-10” polypeptides and comprise an amino acid sequence arrangement from N-terminus to C-terminus in accordance with Formula 1: (first monomer subunit)-LINKER-(second monomer subunit)?? Formula 1 wherein the first monomer subunit, the second monomer subunit or both the first and second monomer subunits may be independently selected from: an unsubstituted IL-10 monomer subunit; or a substituted IL-10 monomer subunit comprising at least one amino acid substitution; and wherein LINKER is any amino acid linker of at least 1-100 amino acids in length.
Type:
Grant
Filed:
May 16, 2019
Date of Patent:
December 27, 2022
Assignee:
ALKERMES, INC.
Inventors:
Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
Type:
Grant
Filed:
September 14, 2020
Date of Patent:
December 6, 2022
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.